Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
22.85
+0.97 (4.43%)
Apr 17, 2026, 4:00 PM EDT - Market closed
Jade Biosciences Employees
Jade Biosciences had 55 employees as of December 31, 2025. The number of employees increased by 25 or 83.33% compared to the previous year.
Employees
55
Change
25
Growth
83.33%
Revenue / Employee
n/a
Profits / Employee
-$1,820,655
Market Cap
1.13B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 25 | 83.33% |
| Dec 31, 2024 | 30 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| UroGen Pharma | 291 |
| Geron | 258 |
| uniQure | 221 |
| Septerna | 130 |
| ORIC Pharmaceuticals | 104 |
| Annexon | 96 |
| Inventiva | 84 |
JBIO News
- 6 weeks ago - Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Jade Biosciences to Participate in Upcoming Conferences - GlobeNewsWire
- 3 months ago - Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Jade Biosciences Announces $45 Million Private Placement - GlobeNewsWire
- 5 months ago - Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 - GlobeNewsWire
- 6 months ago - Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 - GlobeNewsWire
- 6 months ago - Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases - GlobeNewsWire